Evidence map›Paper›PMID 41258420›Full record

ArticleNPJ precision oncology2025

Paired tumor-normal sequencing provides insights into the CDKN2A-associated tumor spectrum.

Kelsey E Breen, Nikita Mehta, Vignesh Ravichandran, Miika Mehine, Chuan Gao, Elise Fiala, Semanti Mukherjee, Ming Gao, Kanika Arora, Yelena Kemel and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Double jeopardy: howFrontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Kelsey E Breen *Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikita Mehta *Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vignesh RavichandranMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Miika MehineDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chuan GaoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elise FialaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Semanti MukherjeeDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ming GaoDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kanika AroraSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yelena KemelSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sydney RothDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Angela G ArnoldDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer KennedyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Margaret SheehanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Faith MurphyDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ryan PtashkinDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew LinDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael WalshDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ozge Ceyhan-BirsoyDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William D TapDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vineet RolstonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yonina R Murciano-GoroffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alicia LathamDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zsofia K StadlerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth OffitDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Diana MandelkerDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mandelkd@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Germline pathogenic variants (PV) in CDKN2A are characterized by an increased risk for melanoma, pancreatic cancer, nervous system tumors, and additional cancer types. We sought to define the tumor and clinical characteristics in a cohort of cancer patients with CDKN2A PV. Amongst 71,868 patients, 69 (0.1%) had a CDKN2A PV. Of these, 87.0% (n = 60), 7.2% (n = 5), and 5.8% (n = 4) had a PV impacting p16

Identifiers

PMID41258420
PMCPMC12630871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.